Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma
1 other identifier
observational
300
14 countries
49
Brief Summary
International retrospective observational cohort study aimed to describe a molecular classification for NMZL.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2024
Typical duration for all trials
49 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 17, 2023
CompletedFirst Posted
Study publicly available on registry
January 26, 2023
CompletedStudy Start
First participant enrolled
April 11, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2026
June 22, 2026
June 1, 2026
2.7 years
January 17, 2023
June 18, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Define and quantify molecular subsets.
Two years: from the end of samples collection to the end of study analysis
Eligibility Criteria
Patients with diagnosis of NMZL on lymph node histology
You may qualify if:
- Male or female adults 18 years or older
- Diagnosis of NMZL on lymph node histology after Jan 1st, 2000
- Availability of tumor material from lymph node (either frozen or FFPE) collected when the patient was treatment naïve
- Availability of the baseline and follow-up annotations
You may not qualify if:
- \. Nodal spread of a clinically occult extranodal MZL (this must have been ruled out by carefully evaluating the extranodal tissues draining to the involved lymph nodes by imaging or endoscopy)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (50)
University of Miami
Miami, Florida, 33136, United States
Mayo Clinic
Rochester, Minnesota, 55905, United States
Weill Cornell Medical
New York, New York, 10065, United States
Ohio Health Riverside Methodist Hospital
Columbus, Ohio, 43214, United States
Hospital Italiano de Buenos Aires
Buenos Aires, C1199ABB, Argentina
Hematology Center after Prof. Yeolyan
Yerevan, Armenia
Princess Margaret Cancer Centre
Toronto, Canada
University Hospital Centre Zagreb
Zagreb, 10000, Croatia
CHU Grenoble Alpes
Grenoble, 38043, France
Institut Universitaire du Cancer de Toulouse
Toulouse, 31059, France
Tata Memorial Hospital
Mumbai, India
AO SS Antonio e Biagio e C. Arrigo
Alessandria, AL, 15121, Italy
Istituto Tumori "Giovanni Paolo II" I.R.C.C.S.
Bari, BA, 70124, Italy
ASST Papa Giovanni XXIII
Bergamo, BG, 24127, Italy
ASST degli Spedali Civili di Brescia
Brescia, BS, 25123, Italy
AOU Policlinico Vittorio Emanuele, Presidio Ferrarotto
Catania, CT, 95123, Italy
Azienda Ospedaliero Universitaria di Ferrara
Cona, FE, 44124, Italy
Azienda Ospedaliera Universitaria Careggi
Florence, FI, 50134, Italy
Azienda Ospedaliera Papardo
Messina, ME, 98158, Italy
IRCCS Ospedale San Raffaele
Milan, MI, 20132, Italy
IEO Istituto Europeo di Oncologia
Milan, MI, 20141, Italy
ASST Grande Ospedale Metropolitano Niguarda
Milan, MI, 20162, Italy
Azienda Sanitaria Locale di Pescara
Pescara, PE, 65124, Italy
Centro di Riferimento Oncologico
Aviano, PN, 33081, Italy
Fondazione IRCCS Policlinico San Matteo
Pavia, PV, 27100, Italy
AUSL IRCCS di Reggio Emilia, Arcispedale S. Maria Nuova
Reggio Emilia, RE, 42123, Italy
Fondazione PTV - Policlinico Tor Vergata
Rome, RM, 00133, Italy
Sapienza University - AOU Policlinico Umberto I
Rome, RM, 00161, Italy
Fondazione Policlinico Univeristario A. Gemelli, IRCCS, Università Cattolica S. Cuore
Rome, RM, 00168, Italy
ASST dei Sette Laghi - Ospedale di Circolo di Varese
Varese, VA, 21100, Italy
IRCCS - Azienda Ospedaliero-Universitaria di Bologna
Bologna, 40138, Italy
Azienda Ospedaliera Universitaria Federico II
Naples, 80131, Italy
AOU Maggiore della Carità
Novara, 28100, Italy
Rijnstate Hospital
Arnhem, Netherlands
University Clinical Center, Medical University of Gdansk
Gdansk, 80-211, Poland
Portuguese Institute of Oncology
Lisbon, 1099-023, Portugal
Chonnam National University Hwasun Hospital
Jeollanam-do, 58128, South Korea
Hospital del Mar
Barcelona, 08003, Spain
Hospital Clinic I Provincial de Barcelona
Barcelona, 08036, Spain
Hospital Universitari de Bellvitge / Institut Català d'Oncologia
L'Hospitalet de Llobregat, 08907, Spain
University Hospital Basel
Basel, Switzerland
Oncology Institute of Southern Switzerland and Institute of Oncology Research
Bellinzona, 6500, Switzerland
Hôpitaux Universitaires Genevois
Geneva, Switzerland
Kantonsspital St. Gallen
Sankt Gallen, 9007, Switzerland
University Hospital Zurich
Zurich, 8091, Switzerland
Royal Bournemouth Hospital
Bournemouth, BH7 7DW, United Kingdom
Leicester Royal Infirmary
Leicester, LE1 5WW, United Kingdom
Clatterbridge Cancer Centre Liverpool
Liverpool, L7 8YA, United Kingdom
Norfolk and Norwich University Hospital
Norwich, NR4 7UY, United Kingdom
Oxford University Hospitals
Oxford, OX3 7LE, United Kingdom
Biospecimen
Tumor biological material of patients with diagnosis of NMZL
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Davide Rossi, MD
Oncology Institute of Southern Switzerland and Institute of Oncology Research
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 17, 2023
First Posted
January 26, 2023
Study Start
April 11, 2024
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
December 31, 2026
Last Updated
June 22, 2026
Record last verified: 2026-06